Costa A, Conget I, Treserras R, Gomis R
Servicio de Endocrinología, Hospital Clínic i Provincial, Universitat de Barcelona.
Med Clin (Barc). 1999 Feb 27;112(7):241-4.
Type 2 diabetes mellitus (DM 2) constitutes today one of the most important problems in terms of health. Nowadays, there is special interest to identify those subjects with a high risk for developing the disease. Our study aimed to evaluate fasting glycemia and glycated hemoglobin in the screening of defects in oral glucose tolerance, in relatives of patients with DM 2.
111 relatives of patients with DM 2 were consecutively included in the study. Glycated hemoglobin (HbA1c, DCA 2000) was measured, afterwards an oral glucose tolerance test (OGTT) was performed. 120 min glycemia (G120) classified oral glucose tolerance as: normal (NGT), impaired glucose tolerance (IGT) and DM. In a first subgroup (n = 80) the equation to predict G120 was obtained (G120 estimated) from the basal glycemia (GO) and HbA1c. In a second subgroup (n = 31), G120 observed after the OGTT (G120 observed) and G120 estimated were compared. Finally, sensitivity, specificity and positive predictive value (PPV) for different cutpoints of GO and G120 were estimated, in order to identify those subjects with abnormal glucose tolerance (IGT and DM).
Considering the results from the first subgroup of subjects, G120 was independently related with GO (R2 = 0.64) and with HbA1c (R2 = 0.62). When GO and HbA1c were considered altogether R2 value was 0.73. When data from the second subgroup of subjects was analysed we did not find any differences between observed G120 and G120 estimated by the equation. The sensitivity, specificity and PPV to detect abnormalities in oral glucose tolerance of estimated G120 were 80, 76 and 61%, respectively. Optimal values of these parameters were obtained with GO 98-102 mg/dl and Hba1c 5.6-5.8%.
Our results confirm that the measurement of GO and HbA1c in first degree relatives of patients with DM 2 is extremely useful to identify those subjects in which abnormal oral glucose tolerance is highly probable.
2型糖尿病(DM 2)如今是最重要的健康问题之一。目前,人们对识别那些患该疾病风险高的个体有着特别的兴趣。我们的研究旨在评估空腹血糖和糖化血红蛋白在筛查DM 2患者亲属口服葡萄糖耐量缺陷中的作用。
111名DM 2患者的亲属被连续纳入本研究。测量糖化血红蛋白(HbA1c,DCA 2000),之后进行口服葡萄糖耐量试验(OGTT)。120分钟血糖(G120)将口服葡萄糖耐量分为:正常(NGT)、糖耐量受损(IGT)和糖尿病。在第一个亚组(n = 80)中,从基础血糖(GO)和HbA1c得出预测G120的方程(估计的G120)。在第二个亚组(n = 31)中,比较OGTT后观察到的G120(观察到的G120)和估计的G120。最后,估计GO和G120不同切点的敏感性、特异性和阳性预测值(PPV),以识别那些葡萄糖耐量异常(IGT和糖尿病)的个体。
考虑第一个亚组对象的结果,G120与GO独立相关(R2 = 0.64),与HbA1c也独立相关(R2 = 0.62)。当同时考虑GO和HbA1c时,R2值为0.73。分析第二个亚组对象的数据时,我们未发现观察到的G120与方程估计的G120之间存在任何差异。估计的G120检测口服葡萄糖耐量异常的敏感性、特异性和PPV分别为80%、76%和61%。这些参数的最佳值在GO为98 - 102 mg/dl和Hba1c为5.6 - 5.8%时获得。
我们的结果证实,在DM 2患者的一级亲属中测量GO和HbA1c对于识别那些极有可能存在口服葡萄糖耐量异常的个体极为有用。